EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy

Study limitation reported by the research below: “This is an expert consensus guidance document, not a systematic review or meta-analysis; individual recommendations are based on regulatory data and expert opinion rather than head-to-head trial evidence.”